A new probiotic treatment to prevent brain issues in premature infants
A novel live biologic for the prevention and treatment of NEC-induced neurodevelopmental impairment
['FUNDING_R01'] · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · NIH-11195672
This study is testing a new way to give probiotics to premature babies, especially those with a serious gut condition called NEC, to help protect their brain development and reduce inflammation.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH INST NATIONWIDE CHILDREN'S HOSP (nih funded) |
| Locations | 1 site (COLUMBUS, UNITED STATES) |
| Trial ID | NIH-11195672 on ClinicalTrials.gov |
What this research studies
This research investigates a novel probiotic delivery system designed to prevent neurodevelopmental impairment (NI) in premature infants, particularly those affected by neonatal necrotizing enterocolitis (NEC). The approach involves administering the probiotic Limosilactobacillus reuteri in a protective biofilm that enhances its beneficial properties and reduces inflammation. By studying the effects of this treatment in both NEC-affected and healthy control pups, the researchers aim to optimize dosing regimens that could mitigate the long-term impacts of NEC on brain development.
Who could benefit from this research
Good fit: Ideal candidates for this research are premature infants born before 31 weeks of gestation, particularly those at risk for NEC.
Not a fit: Patients who are not premature or do not have a risk of NEC may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of neurodevelopmental impairment in premature infants, leading to better long-term health outcomes.
How similar studies have performed: Previous research has shown promise in using probiotics to reduce inflammation and improve outcomes in similar populations, suggesting a potential for success with this novel approach.
Where this research is happening
COLUMBUS, UNITED STATES
- RESEARCH INST NATIONWIDE CHILDREN'S HOSP — COLUMBUS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BAILEY, MICHAEL T — RESEARCH INST NATIONWIDE CHILDREN'S HOSP
- Study coordinator: BAILEY, MICHAEL T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired brain injury